CA2557075A1 - Composes inhibiteurs de methylation - Google Patents

Composes inhibiteurs de methylation Download PDF

Info

Publication number
CA2557075A1
CA2557075A1 CA002557075A CA2557075A CA2557075A1 CA 2557075 A1 CA2557075 A1 CA 2557075A1 CA 002557075 A CA002557075 A CA 002557075A CA 2557075 A CA2557075 A CA 2557075A CA 2557075 A1 CA2557075 A1 CA 2557075A1
Authority
CA
Canada
Prior art keywords
compound
formula
dna
cell
zeb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002557075A
Other languages
English (en)
Inventor
Victor E. Marquez
James A. Kelly
Riad Ag-Baria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Office Of Technology Transf
Victor E. Marquez
James A. Kelly
Riad Ag-Baria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Office Of Technology Transf, Victor E. Marquez, James A. Kelly, Riad Ag-Baria filed Critical Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Office Of Technology Transf
Publication of CA2557075A1 publication Critical patent/CA2557075A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002557075A 2004-02-25 2005-02-25 Composes inhibiteurs de methylation Abandoned CA2557075A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54790204P 2004-02-25 2004-02-25
US60/547,902 2004-02-25
PCT/US2005/006173 WO2005082144A1 (fr) 2004-02-25 2005-02-25 Composes inhibiteurs de methylation

Publications (1)

Publication Number Publication Date
CA2557075A1 true CA2557075A1 (fr) 2005-09-09

Family

ID=34910960

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002557075A Abandoned CA2557075A1 (fr) 2004-02-25 2005-02-25 Composes inhibiteurs de methylation

Country Status (4)

Country Link
EP (1) EP1718150A1 (fr)
AU (1) AU2005216971A1 (fr)
CA (1) CA2557075A1 (fr)
WO (1) WO2005082144A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508885A (ja) 2001-07-31 2005-04-07 ザ ステイト オブ オレゴン， アクティング バイ アンド スルー ザ ステイト ボード オブ ハイヤー エデュケイション オン ビハーフ オブ ザ ユニバーシティー オブ オレゴン Ｄｎａメチル化の阻害剤
DE102006059294B4 (de) * 2006-12-13 2011-01-20 International University Bremen Gmbh Methylierungsinhibitor für eine eukaryontische Nukleinsäure-Methylierungsreaktion, dessen Verwendung, Inhibierungsverfahren und Bestimmungsverfahren der Inhibierungswirkung
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
DE102007022274A1 (de) * 2007-05-09 2008-11-20 Jacobs University Bremen Ggmbh Verfahren und Reagenzien zur Untersuchung von Nukleinsäure-Methylierungsreaktionen
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
EP3620532B1 (fr) * 2009-04-20 2021-12-22 Erasmus University Medical Center Rotterdam Procédé de diagnostic de cancer de la vessie
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CN104017020B (zh) 2010-03-31 2017-04-12 吉利德制药有限责任公司 核苷氨基磷酸酯
WO2012075140A1 (fr) 2010-11-30 2012-06-07 Pharmasset, Inc. Composés
HUE036588T2 (hu) 2011-09-16 2018-07-30 Gilead Pharmasset Llc Eljárások HCV kezelésére
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
LT2950786T (lt) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2259041A1 (fr) * 1997-04-28 1998-11-05 Arsinur Burcoglu Traitement de l'infection par vih et de ses infections opportunistes
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase

Also Published As

Publication number Publication date
EP1718150A1 (fr) 2006-11-08
WO2005082144A1 (fr) 2005-09-09
AU2005216971A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
CA2557075A1 (fr) Composes inhibiteurs de methylation
Ben-Kasus et al. Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells
US8158605B2 (en) Azacytidine analogues and uses thereof
EP2276774B1 (fr) Substances thérapeutiques qui modulent la méthylation du génome
HU228064B1 (en) New antiviral nucleoside derivatives
US10758558B2 (en) Hybrid oligonucleotides and uses thereof
JP2005524662A (ja) ヌクレオシド５’−一リン酸模倣物およびこれらのプロドラッグ
KR20080059612A (ko) 5-아자-시토신이 내부에 삽입된 올리고뉴클레오티드 유사체
JP2010202655A (ja) チオアラビノフラノシル化合物の製造方法
CN104955818A (zh) 核苷激酶旁路组合物和方法
Tan et al. Ribavirin targets eIF4E dependent Akt survival signaling
Yu et al. Anticancer drug discovery targeting DNA hypermethylation
EP1015472A1 (fr) Utilisations de la nicotinamide adenine dinucleotide et de ses analogues dans le traitement des affections malignes et des maladies infectieuses
TW201728341A (zh) 肽寡核苷酸結合物
EP3068406B1 (fr) Promédicament réciproque comportant des acides gras à chaîne courte et de la zébularine ou de la 1'-cyano-cytarabine pour un traitement de cancer
Konstantinov et al. Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies
WO2022234855A1 (fr) Procédé de conception d'un oligonucléotide ayant une toxicité centrale réduite
RU2112766C1 (ru) Олигонуклеотиды, фармацевтическая композиция
Beltran et al. Rational design of a new series of pronucleotide
Szymanska-Michalak et al. New antiglioma zwitterionic pronucleotides with an FdUMP framework
Shuto et al. Nucleosides and nucleotides. 150. Enzymatic synthesis of 5′-phosphatidyl derivatives of 1-(2-C-cyano-2-deoxy-β-d-arabino-pentofuranosyl) cytosine (CNDAC) and their notable antitumor effects in mice1
US6395312B1 (en) Echinops extract with anti-cancer activity
RU2487883C2 (ru) Аналоги азацитидина и их применение
TR2022021488A2 (tr) Mi̇dekanseri̇ kemoterapi̇ tedavi̇si̇nde kullanilmak üzere geli̇şti̇ri̇len kompozi̇syon
JP2006521283A (ja) ５−置換ヌクレオシドの使用

Legal Events

Date Code Title Description
FZDE Discontinued